Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 20, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Market Cap	224	771	482	538	804	1,363
Market Cap Growth	-76.67%	60.15%	-10.40%	-33.17%	-40.97%	382.72%
Enterprise Value	92.52	668.77	349.45	386.51	655.21	1,211
Last Close Price	2.42	8.90	5.68	6.55	10.32	17.95
Forward PE	-	10.73	-	-	-	-
PB Ratio	1.77	8.13	4.00	3.79	5.65	9.04
P/TBV Ratio	1.65	8.00	3.94	3.68	5.57	8.31
Net Debt / Equity Ratio	-1.04	-1.08	-1.10	-1.06	-1.05	-1.01
Net Debt / EBITDA Ratio	2.95	2.00	2.50	2.71	2.93	3.62
Net Debt / FCF Ratio	3.87	2.63	4.29	5.44	6.15	5.01
Quick Ratio	20.81	11.56	8.80	12.27	14.92	14.93
Current Ratio	20.87	11.60	8.86	12.32	14.95	14.97
Return on Equity (ROE)	-4.78%	-43.11%	-32.81%	-33.41%	-32.47%	-42.28%
Return on Assets (ROA)	-34.92%	-42.95%	-36.47%	-36.32%	-32.44%	-42.82%
Return on Capital Employed (ROCE)	-37.55%	-47.79%	-40.35%	-39.22%	-34.77%	-47.18%
Buyback Yield / Dilution	-2.61%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%
Total Shareholder Return	-2.61%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Feb 9, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 20, 2026

Data Sources Report a data error